(19)
(11) EP 2 864 328 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
24.01.2018 Bulletin 2018/04

(45) Mention of the grant of the patent:
06.12.2017 Bulletin 2017/49

(21) Application number: 13731470.4

(22) Date of filing: 21.06.2013
(51) International Patent Classification (IPC): 
C07D 471/04(2006.01)
 C07D 471/06(2006.01)
(86) International application number:
PCT/GB2013/051633
(87) International publication number:
WO 2013/190319 (27.12.2013 Gazette 2013/52)

(54)

PHARMACEUTICALLY ACTIVE COMPOUNDS

PHARMAZEUTISCH AKTIVE VERBINDUNGEN

COMPOSÉS PHARMACEUTIQUEMENT ACTIFS

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 21.06.2012 GB 201211021

(43) Date of publication of application:
29.04.2015 Bulletin 2015/18

(73) Proprietor: The Institute of Cancer Research: Royal Cancer Hospital
London SW7 3RP (GB)

(72) Inventors:
  • BLAGG, Julian
    Sutton SM2 5NG (GB)
  • BAVETSIAS, Vassilios
    Sutton SM2 5NG (GB)
  • MOORE, Andrew S.
    Herston, Queensland 4029 (AU)
  • LINARDOPOULOS, Spyridon
    Sutton SM2 5NG (GB)

(74) Representative: HGF Limited 
4th Floor Merchant Exchange 17-19 Whitworth Street West
Manchester M1 5WG
Manchester M1 5WG (GB)


(56) References cited: : 
WO-A1-2009/001021
 WO-A2-2007/072017
   
  • V. BAVETSIAS ET AL: "Optimization of Imidazo[4,5-b]pyrimidine-Based Kinase Inhibitors: Identification of a Dual FL%3/Auroa Kinase Inhibitor as an orally Bioavailable Preclinical Development Candidate for the Treatment of Acute Myeloid Leukemia", JOURNAL OF MEDICINAL CHEMISTRY, vol. 55, no. 20, 8 October 2012 (2012-10-08), pages 8721-8734, XP002702452, DOI: 10.1021/jm300952s
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).